Bausch Health Companies Inc. (BHC)
NYSE · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$6.26 (-1.50%) as of
Key statistics
- Market cap
- 2.34B
- Forward P/E
- 1.46
- EPS (TTM)
- -2.95
- Dividend yield
- 0.00%
- 52-week range
- 4.33 – 8.00
- Beta
- 0.37
- Revenue (TTM)
- 10.85B
- Profit margin
- -10.12%
- Analyst target
- $7.50
- Volume
- 606.09k
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Laval, QC, Canada
- Employees
- 20,300
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.